Association of neuronal injury blood marker neurofilament light chain with mild-to-moderate COVID-19

被引：0
|
作者：
Markus Ameres
Susanne Brandstetter
Antoaneta A. Toncheva
Michael Kabesch
David Leppert
Jens Kuhle
Sven Wellmann
机构：
[1] University of Regensburg,University Children’s Hospital Regensburg (KUNO), Hospital St. Hedwig of the Order of St. John
[2] University of Regensburg,Research and Development Campus Regensburg (WECARE) at the Hospital St. Hedwig of the Order of St. John
[3] University Hospital Basel,Neurologic Clinic and Policlinic, Departments of Medicine, Biomedicine and Clinical Research
[4] University of Basel,undefined
来源：
Journal of Neurology | 2020年 / 267卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：3476 / 3478
页数：2
相关论文
共 50 条
  • [31] Considerations for Return to Exercise following Mild-to-Moderate COVID-19 in the Recreational Athlete
    Metzl, Jordan D.
    McElheny, Kathryn
    Robinson, James N.
    Scott, Daphne A.
    Sutton, Karen M.
    Toresdahl, Brett G.
    HSS JOURNAL, 2020, 16 (1_SUPPL) : 102 - 107
  • [32] Cognitive Impairment in Non-critical, Mild-to-Moderate COVID-19 Survivors
    Henneghan, Ashley M.
    Lewis, Kimberly A.
    Gill, Eliana
    Kesler, Shelli R.
    FRONTIERS IN PSYCHOLOGY, 2022, 13
  • [33] Monoclonal Antibody and Antiviral Therapy for Mild-to-Moderate COVID-19 in Pediatric Patients
    Vora, Surabhi B. B.
    Englund, Janet A. A.
    Trehan, Indi
    Waghmare, Alpana
    Kong, Ada
    Adler, Amanda
    Zerr, Danielle M. M.
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2023, 42 (01) : 32 - 34
  • [34] Integrative medicine considerations for convalescence from mild-to-moderate COVID-19 disease
    Alschuler, Lise
    Chiasson, Ann Marie
    Horwitz, Randy
    Sternberg, Esther
    Crocker, Robert
    Weil, Andrew
    Maizes, Victoria
    EXPLORE-THE JOURNAL OF SCIENCE AND HEALING, 2022, 18 (02) : 140 - 148
  • [35] A Randomized Placebo-Controlled Trial of Leronlimab in Mild-To-Moderate COVID-19
    Seethamraju, Harish
    Yang, Otto O.
    Loftus, Richard
    Ogbuagu, Onyema
    Sammartino, Daniel
    Mansour, Ali
    Sacha, Jonah B.
    Ojha, Sohita
    Hansen, Scott G.
    Arman, Arvin Cyrus
    Lalezari, Jacob P.
    CLINICAL THERAPEUTICS, 2024, 46 (11) : 891 - 899
  • [36] The efficacy of neutralizing monoclonal antibodies in transplant recipients with mild-to-moderate COVID-19
    Arimura, Ken
    Tagaya, Etsuko
    Kikuchi, Ken
    Mitsuda, Toshihiro
    Ebihara, Fumiya
    Maruyama, Takumi
    Hamada, Yukihiro
    Unagami, Kohei
    Kanzawa, Taichi
    Sekiguchi, Haruki
    Shimamoto, Ken
    Ishida, Hideki
    Egawa, Hiroto
    Tanaka, Junji
    Kawana, Masatoshi
    TRANSPLANT IMMUNOLOGY, 2023, 77
  • [37] Monoclonal antibodies for mild-to-moderate COVID-19 in multiple sclerosis: A case series
    Moccia, Marcello
    Buonomo, Antonio Riccardo
    Scotto, Riccardo
    Viceconte, Giulio
    Nobile, Mariano
    Lanzillo, Roberta
    Morra, Vincenzo Brescia
    Gentile, Ivan
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2022, 439
  • [38] Clinical Pathways When Considering Antimicrobials for the Treatment of Mild-to-Moderate COVID-19
    Krauth, Daniel S.
    MILITARY MEDICINE, 2022, 187 (7-8) : 186 - 188
  • [39] Mild-to-moderate COVID-19 may affect nervous system function in convalescents
    Lulek, M.
    Malecka-Gieldowska, M.
    Ciepiela, O.
    CLINICA CHIMICA ACTA, 2024, 558 : 2 - 3
  • [40] Bamlanivimab use in mild-to-moderate COVID-19 disease: A matched cohort design
    Destache, Christopher J.
    Aurit, Sarah J.
    Schmidt, David
    Erkes, Laura Peet
    Tierney, Maureen
    Vivekanandan, Renuga
    PHARMACOTHERAPY, 2021, 41 (09): : 743 - 747
12345